The high stakes in Sanofi’s appeal of Amgen’s rare permanent injunction win
(UPDATED FEBRUARY 8) Last month’s granting of an Amgen permanent injunction motion in its cholesterol drug patent dispute with Sanofi and Regeneron would “give another arrow in the quiver” of those seeking permanent injunctions in similar cases, if it is upheld on appeal
UPDATE FEBRUARY 8:
The Federal Circuit has stayed
the permanent injunction for Praluent pending Sanofi and
Regeneron's appeal. The story published below on February
7 has been updated to reflect this.
Saying she was caught "between a...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.